176 related articles for article (PubMed ID: 21861100)
21. Extramedullary involvement: an emerging problem in multiple myeloma.
Molica S
Clin Adv Hematol Oncol; 2012 Apr; 10(4):268-9. PubMed ID: 22706492
[No Abstract] [Full Text] [Related]
22. Inefficacy of bortezomib therapy for CNS involvement of refractory multiple myeloma.
Mele G; Pinna S; Alloro E; Brocca MC; Coppi MR; Quarta G
Leuk Res; 2007 May; 31(5):721-3. PubMed ID: 16890285
[No Abstract] [Full Text] [Related]
23. Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.
Khan AA; Siraj F; Bhargava M; Aggarwal S
BMJ Case Rep; 2012 Dec; 2012():. PubMed ID: 23264156
[TBL] [Abstract][Full Text] [Related]
24. Bone building with bortezomib.
Roodman GD
J Clin Invest; 2008 Feb; 118(2):462-4. PubMed ID: 18219395
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib data show improved survival in patients with relapsed multiple myeloma.
Oncology (Williston Park); 2004 Aug; 18(9):1199, 1201. PubMed ID: 15471202
[No Abstract] [Full Text] [Related]
26. Shoulder X-ray--a clue to multiple myeloma.
Sharma V; Nagaraj S; Joshi VR
J Assoc Physicians India; 2012 Mar; 60():48. PubMed ID: 22799115
[No Abstract] [Full Text] [Related]
27. New developments with bortezomib in treating multiple myeloma.
Reddy GK
Clin Lymphoma; 2004 Mar; 4(4):215-6. PubMed ID: 15072611
[No Abstract] [Full Text] [Related]
28. Optimizing bortezomib treatment in patients with relapsed multiple myeloma.
Richardson P
Clin Adv Hematol Oncol; 2006 May; 4(5):4-5; discussion 8; suppl 13. PubMed ID: 16832859
[No Abstract] [Full Text] [Related]
29. Visceral leishmaniasis infection in a refractory multiple myeloma patient treated with bortezomib.
Piro E; Kropp M; Cantaffa R; Lamberti AG; Carillio G; Molica S
Ann Hematol; 2012 Nov; 91(11):1827-8. PubMed ID: 22584850
[No Abstract] [Full Text] [Related]
30. Use of bortezomib in the management of chronic graft-versus-host disease among multiple myeloma patients relapsing after allogeneic transplantation.
Mateos-Mazon J; Pérez-Simón JA; Lopez O; Hernández E; Etxebarria J; San Miguel JF
Haematologica; 2007 Sep; 92(9):1295-6. PubMed ID: 17768136
[TBL] [Abstract][Full Text] [Related]
31. Bortezomib increases survival of patients with relapsed multiple myeloma.
Health News; 2005 Sep; 11(9):9. PubMed ID: 16211682
[No Abstract] [Full Text] [Related]
32. Impact of bortezomib on bone health in myeloma: a review of current evidence.
Zangari M; Terpos E; Zhan F; Tricot G
Cancer Treat Rev; 2012 Dec; 38(8):968-80. PubMed ID: 22226939
[TBL] [Abstract][Full Text] [Related]
33. Hematology: first-line bortezomib benefits patients with multiple myeloma.
Dimopoulos MA; Terpos E
Nat Rev Clin Oncol; 2009 Dec; 6(12):683-5. PubMed ID: 19942924
[TBL] [Abstract][Full Text] [Related]
34. Renal improvement in myeloma with bortezomib plus plasma exchange.
Burnette BL; Leung N; Rajkumar SV
N Engl J Med; 2011 Jun; 364(24):2365-6. PubMed ID: 21675906
[No Abstract] [Full Text] [Related]
35. Bortezomib, thalidomide, and dexamethasone for relapsed multiple myeloma: add it up and wait.
Badros A; Gahres N
Clin Adv Hematol Oncol; 2005 Dec; 3(12):916-7; discussion 918. PubMed ID: 16555432
[No Abstract] [Full Text] [Related]
36. [Safety evaluation of bortezomib in multiple myeloma patients with severe renal failure].
Muta T; Nakanishi H; Yasunaga M; Senba S; Murakami H; Kan S; Ueda Y; Fujisaki T
Gan To Kagaku Ryoho; 2011 Feb; 38(2):237-41. PubMed ID: 21368487
[TBL] [Abstract][Full Text] [Related]
37. Hemostatic effects of bortezomib treatment in patients with relapsed or refractory multiple myeloma.
Zangari M; Guerrero J; Cavallo F; Prasad HK; Esseltine D; Fink L
Haematologica; 2008 Jun; 93(6):953-4. PubMed ID: 18515882
[No Abstract] [Full Text] [Related]
38. Bortezomib in multiple myeloma.
Vandenbroucke JP; Kroep JR
N Engl J Med; 2005 Sep; 353(12):1297-8; author reply 1297-8. PubMed ID: 16180272
[No Abstract] [Full Text] [Related]
39. Analysis of the efficacy and toxicity of bortezomib for treatment of relapsed or refractory multiple myeloma in community practice.
Wu KL; van Wieringen W; Vellenga E; Zweegman S; Lokhorst HM; Sonneveld P
Haematologica; 2005 Jul; 90(7):996-7. PubMed ID: 15996946
[TBL] [Abstract][Full Text] [Related]
40. [Bortezomib in second-line therapy].
Musch A
Med Monatsschr Pharm; 2005 Sep; 28(9):332-3. PubMed ID: 16163891
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
